{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:52:09Z","timestamp":1790855529133,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T00:00:00Z","timestamp":1499385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.atherosclerosis.2017.07.005","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T07:31:45Z","timestamp":1499326305000},"page":"83-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Interleukin-32 in chronic inflammatory conditions is associated with a higher risk of cardiovascular diseases"],"prefix":"10.1016","volume":"264","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4617-2564","authenticated-orcid":false,"given":"Michelle S.M.A.","family":"Damen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calin D.","family":"Popa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai G.","family":"Netea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Dinarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo A.B.","family":"Joosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.atherosclerosis.2017.07.005_bib1","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/gerona\/glu057","article-title":"Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases","volume":"69","author":"Franceschi","year":"2014","journal-title":"J.\u00a0Gerontol. Ser. A Biol. Sci. Med. Sci."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2017.07.005_bib2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and prevention and the American heart association","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2017.07.005_bib3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrcardio.2016.185","article-title":"Inflammatory processes in cardiovascular disease: a route to targeted therapies","volume":"14","author":"Ruparelia","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2017.07.005_bib4","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.autrev.2011.04.018","article-title":"The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk","volume":"10","author":"Gremese","year":"2011","journal-title":"Autoimmun. Rev."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2017.07.005_bib5","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.24092","article-title":"Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"59","author":"Avina-Zubieta","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"Suppl 1","key":"10.1016\/j.atherosclerosis.2017.07.005_bib6","doi-asserted-by":"crossref","first-page":"i61","DOI":"10.1136\/ard.2009.119404","article-title":"Heart disease and rheumatoid arthritis: understanding the risks","volume":"69","author":"Gabriel","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2017.07.005_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2013an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"New Engl. J. Med."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2017.07.005_bib8","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1073\/pnas.0511233103","article-title":"IL-32, a proinflammatory cytokine in rheumatoid arthritis","volume":"103","author":"Joosten","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2017.07.005_bib9","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2011-200493","article-title":"Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis","volume":"71","author":"Charles-Schoeman","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2017.07.005_bib10","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1136\/ard.2006.066191","article-title":"Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis","volume":"66","author":"Popa","year":"2007","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2017.07.005_bib11","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1073\/pnas.0813334106","article-title":"IL-32-dependent effects of IL-1beta on endothelial cell functions","volume":"106","author":"Nold-Petry","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2017.07.005_bib12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cyto.2013.05.002","article-title":"Towards a role of interleukin-32 in atherosclerosis","volume":"64","author":"Heinhuis","year":"2013","journal-title":"Cytokine"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2017.07.005_bib13","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2002-3-7-research0035","article-title":"Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration","volume":"3","author":"Panelli","year":"2002","journal-title":"Genome Biol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2017.07.005_bib14","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4049\/jimmunol.148.2.597","article-title":"Identification of a novel gene expressed in activated natural killer cells and T cells","volume":"148","author":"Dahl","year":"1992","journal-title":"J.\u00a0Immunol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2017.07.005_bib15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0092-8674(86)90259-X","article-title":"Arg-Gly-Asp: a versatile cell recognition signal","volume":"44","author":"Ruoslahti","year":"1986","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2017.07.005_bib16","first-page":"131","article-title":"Interleukin-32: a cytokine and inducer of TNFalpha","volume":"22","author":"Kim","year":"2005","journal-title":"Immunity"},{"issue":"Suppl 3","key":"10.1016\/j.atherosclerosis.2017.07.005_bib17","article-title":"IL-32, a novel cytokine with a possible role in disease","volume":"65","author":"Dinarello","year":"2006","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2017.07.005_bib18","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1074\/jbc.M111.288290","article-title":"Interleukin 32 (IL-32) contains a typical alpha-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1","volume":"287","author":"Heinhuis","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2017.07.005_bib19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4049\/jimmunol.1202802","article-title":"IL-32 promotes angiogenesis","volume":"192","author":"Nold-Petry","year":"2014","journal-title":"J.\u00a0Immunol."},{"issue":"45","key":"10.1016\/j.atherosclerosis.2017.07.005_bib20","doi-asserted-by":"crossref","first-page":"16309","DOI":"10.1073\/pnas.0508237102","article-title":"IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism","volume":"102","author":"Netea","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2017.07.005_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4110\/in.2014.14.3.123","article-title":"Interleukin-32 in inflammatory autoimmune diseases","volume":"14","author":"Kim","year":"2014","journal-title":"Immune Netw."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2017.07.005_bib22","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1164\/rccm.200804-646OC","article-title":"IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease","volume":"178","author":"Calabrese","year":"2008","journal-title":"Am. J. Respir. Crit. care Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2017.07.005_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clim.2013.02.021","article-title":"IL-32 with potential insights into rheumatoid arthritis","volume":"147","author":"Xu","year":"2013","journal-title":"Clin. Immunol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2017.07.005_bib24","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/ard.2010.139196","article-title":"Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade","volume":"70","author":"Heinhuis","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2017.07.005_bib25","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2567.2008.02917.x","article-title":"Identification of the most active interleukin-32 isoform","volume":"126","author":"Choi","year":"2009","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2017.07.005_bib26","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/art.27197","article-title":"Effect of interleukin-32gamma on differentiation of osteoclasts from CD14+ monocytes","volume":"62","author":"Kim","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2017.07.005_bib27","doi-asserted-by":"crossref","first-page":"R246","DOI":"10.1186\/ar4089","article-title":"IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis","volume":"14","author":"Moon","year":"2012","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2017.07.005_bib28","first-page":"289","article-title":"Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine\/chemokine genes differentially expressed by in\u00a0vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes","volume":"16","author":"Cagnard","year":"2005","journal-title":"Eur. Cytokine Netw."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2017.07.005_bib29","first-page":"73","article-title":"Clinical significance of interleukin-32 expression in patients with rheumatoid arthritis","volume":"31","author":"Gui","year":"2013","journal-title":"Asian Pac. J. Allergy Immunol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2017.07.005_bib30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3892\/ijmm.2013.1548","article-title":"Inhibition of IL-32 and TSLP production through the attenuation of caspase-1 activation in an animal model of allergic rhinitis by Naju Jjok (Polygonum tinctorium)","volume":"33","author":"Jeong","year":"2014","journal-title":"Int. J. Mol. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2017.07.005_bib31","first-page":"483","article-title":"A\u00a0new isoform of interleukin-32 suppresses IL-8 mRNA expression in the intestinal epithelial cell line HT-29","volume":"4","author":"Imaeda","year":"2011","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.atherosclerosis.2017.07.005_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40001-015-0083-y","article-title":"A\u00a0panoramic spectrum of complex interplay between the immune system and IL-32 during pathogenesis of various systemic infections and inflammation","volume":"20","author":"Khawar","year":"2015","journal-title":"Eur. J. Med. Res."},{"issue":"7152","key":"10.1016\/j.atherosclerosis.2017.07.005_bib33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature06005","article-title":"Unravelling the pathogenesis of inflammatory bowel disease","volume":"448","author":"Xavier","year":"2007","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2017.07.005_bib34","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.tim.2006.08.008","article-title":"NODs in defence: from vulnerable antimicrobial peptides to chronic inflammation","volume":"14","author":"Peyrin-Biroulet","year":"2006","journal-title":"Trends Microbiol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2017.07.005_bib35","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1365-2249.2007.03439.x","article-title":"Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease","volume":"149","author":"Shioya","year":"2007","journal-title":"Clin. Exp. Immunol."},{"issue":"49","key":"10.1016\/j.atherosclerosis.2017.07.005_bib36","doi-asserted-by":"crossref","first-page":"21082","DOI":"10.1073\/pnas.1015418107","article-title":"Paradoxical effects of constitutive human IL-32{gamma} in transgenic mice during experimental colitis","volume":"107","author":"Choi","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1 Suppl","key":"10.1016\/j.atherosclerosis.2017.07.005_bib37","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1111\/j.1365-2567.2008.03025.x","article-title":"A\u00a0proinflammatory cytokine interleukin-32beta promotes the production of an anti-inflammatory cytokine interleukin-10","volume":"128","author":"Kang","year":"2009","journal-title":"Immunology"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2017.07.005_bib38","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1073\/pnas.0712381105","article-title":"Interleukin-32 induces the differentiation of monocytes into macrophage-like cells","volume":"105","author":"Netea","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2017.07.005_bib39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1465-9921-13-19","article-title":"Oxidative stress induced interleukin-32 mRNA expression in human bronchial epithelial cells","volume":"13","author":"Kudo","year":"2012","journal-title":"Respir. Res."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2017.07.005_bib40","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/thx.2003.019588","article-title":"Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis","volume":"59","author":"Gan","year":"2004","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2017.07.005_bib41","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1165\/rcmb.2006-0199TR","article-title":"Role of viral infections in asthma and chronic obstructive pulmonary disease","volume":"35","author":"Proud","year":"2006","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2017.07.005_bib42","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.autrev.2005.12.006","article-title":"Inflammation: a pivotal link between autoimmune diseases and atherosclerosis","volume":"5","author":"Abou-Raya","year":"2006","journal-title":"Autoimmun. Rev."},{"issue":"21","key":"10.1016\/j.atherosclerosis.2017.07.005_bib43","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1161\/01.CIR.100.21.2124","article-title":"A\u00a0tale of two diseases: atherosclerosis and rheumatoid arthritis","volume":"100","author":"Pasceri","year":"1999","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2017.07.005_bib44","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1002\/1529-0131(200112)44:12<2707::AID-ART456>3.0.CO;2-M","article-title":"Nails in the coffin: increasing evidence for the role of rheumatic disease in the cardiovascular mortality of rheumatoid arthritis","volume":"44","author":"Bacon","year":"2001","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2017.07.005_bib45","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2010.02.029","article-title":"Nonresolving inflammation","volume":"140","author":"Nathan","year":"2010","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2017.07.005_bib46","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-009-0153-8","article-title":"Innate and adaptive immunity in atherosclerosis","volume":"31","author":"Packard","year":"2009","journal-title":"Semin. Immunopathol."},{"issue":"21","key":"10.1016\/j.atherosclerosis.2017.07.005_bib47","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1161\/01.CIR.100.21.2135","article-title":"Perturbation of the T-cell repertoire in patients with unstable angina","volume":"100","author":"Liuzzo","year":"1999","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.atherosclerosis.2017.07.005_bib48","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1161\/01.CIR.0000131450.66017.B3","article-title":"CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients","volume":"109","author":"Gerli","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2017.07.005_bib49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.bor.0000149084.16639.b0","article-title":"Endothelial cell dysfunction in systemic vasculitis: new developments and therapeutic prospects","volume":"17","author":"Bacon","year":"2005","journal-title":"Curr. Opin. Rheumatol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2017.07.005_bib50","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/01.mol.0000180164.70077.a7","article-title":"A\u00a0proatherogenic role for C-reactive protein in\u00a0vivo","volume":"16","author":"Paul","year":"2005","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2017.07.005_bib51","article-title":"Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data","volume":"342","author":"Wensley","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2017.07.005_bib52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-Reactive protein to Interleukin-6 to Interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2017.07.005_bib53","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11926-012-0313-z","article-title":"Cholesterol crystals and inflammation","volume":"15","author":"Grebe","year":"2013","journal-title":"Curr. Rheumatol. Rep."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2017.07.005_bib54","first-page":"1701","article-title":"Lipid profiles in untreated patients with rheumatoid arthritis","volume":"26","author":"Park","year":"1999","journal-title":"J.\u00a0Rheumatol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2017.07.005_bib55","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/ard.2006.051672","article-title":"Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis","volume":"66","author":"van Halm","year":"2007","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2017.07.005_bib56","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1194\/jlr.R600021-JLR200","article-title":"The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk","volume":"48","author":"Popa","year":"2007","journal-title":"J.\u00a0Lipid Res."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2017.07.005_bib57","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/art.21976","article-title":"Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"54","author":"McMahon","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2017.07.005_bib58","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1136\/ard.2008.092171","article-title":"Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients","volume":"68","author":"Popa","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2017.07.005_bib59","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCRESAHA.114.300935","article-title":"High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target","volume":"114","author":"Luscher","year":"2014","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2017.07.005_bib60","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0022-2275(20)40131-2","article-title":"Formation of cholesterol monohydrate crystals in macrophage-derived foam cells","volume":"35","author":"Tangirala","year":"1994","journal-title":"J.\u00a0Lipid Res."},{"issue":"7293","key":"10.1016\/j.atherosclerosis.2017.07.005_bib61","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2017.07.005_bib62","doi-asserted-by":"crossref","first-page":"e11765","DOI":"10.1371\/journal.pone.0011765","article-title":"Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation","volume":"5","author":"Rajamaki","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2017.07.005_bib63","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.18","article-title":"Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome","volume":"2","author":"Menu","year":"2011","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2017.07.005_bib64","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/01.ATV.0000064374.15232.C3","article-title":"Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice","volume":"23","author":"Kirii","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"36","key":"10.1016\/j.atherosclerosis.2017.07.005_bib65","doi-asserted-by":"crossref","first-page":"38566","DOI":"10.18632\/oncotarget.6160","article-title":"Decreased severity of collagen antibody and lipopolysaccharide-induced arthritis in human IL-32beta overexpressed transgenic mice","volume":"6","author":"Park","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2017.07.005_bib66","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.4049\/jimmunol.0901913","article-title":"IL-32 is a host protective cytokine against Mycobacterium tuberculosis in differentiated THP-1 human macrophages","volume":"184","author":"Bai","year":"2010","journal-title":"J.\u00a0Immunol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2017.07.005_bib67","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2004.11.016","article-title":"Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice","volume":"180","author":"Ohta","year":"2005","journal-title":"Atherosclerosis"},{"issue":"18","key":"10.1016\/j.atherosclerosis.2017.07.005_bib68","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/01.CIR.101.18.2149","article-title":"Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction","volume":"101","author":"Ridker","year":"2000","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2017.07.005_bib69","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1160\/TH07-01-0036","article-title":"The specific role of chemokines in atherosclerosis","volume":"97","author":"Braunersreuther","year":"2007","journal-title":"Thromb. Haemostasis"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2017.07.005_bib70","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1084\/jem.20050640","article-title":"Blocking IL-1 in systemic inflammation","volume":"201","author":"Dinarello","year":"2005","journal-title":"J.\u00a0Exp. Med."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2017.07.005_bib71","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.cyto.2009.03.007","article-title":"Molecular characterization of IL-32 in human endothelial cells","volume":"46","author":"Kobayashi","year":"2009","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2017.07.005_bib72","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.4049\/jimmunol.0902283","article-title":"IFN-gamma primes intact human coronary arteries and cultured coronary smooth muscle cells to double-stranded RNA- and self-RNA-induced inflammatory responses by upregulating TLR3 and melanoma differentiation-associated gene 5","volume":"185","author":"Ahmad","year":"2010","journal-title":"J.\u00a0Immunol."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2017.07.005_bib73","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/art.21278","article-title":"The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7\/8 results in synergistic cytokine production by dendritic cells","volume":"52","author":"Roelofs","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2017.07.005_bib74","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrcardio.2015.124","article-title":"Dysfunctional HDL and atherosclerotic cardiovascular disease","volume":"13","author":"Rosenson","year":"2016","journal-title":"Nat. Rev. Cardiol."},{"issue":"Suppl 2","key":"10.1016\/j.atherosclerosis.2017.07.005_bib75","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/annrheumdis-2015-eular.5540","article-title":"SAT0025 shift in genetic composition of an IL-32 promoter polymorphism results in a higher cytokine production in RA patients","volume":"74","author":"Damen MSMAH","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.atherosclerosis.2017.07.005_bib76","doi-asserted-by":"crossref","first-page":"41629","DOI":"10.1038\/srep41629","article-title":"IL-32 promoter SNP rs4786370 predisposes to modified lipoprotein profiles in patients with rheumatoid arthritis","volume":"7","author":"Damen","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915017311802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915017311802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T10:55:34Z","timestamp":1750503334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915017311802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":76,"alternative-id":["S0021915017311802"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.07.005","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-32 in chronic inflammatory conditions is associated with a higher risk of cardiovascular diseases","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}